Yang Guangyi, Ge Shufan, Singh Rashim, Basu Sumit, Shatzer Katherine, Zen Ming, Liu Jiong, Tu Yifan, Zhang Chenning, Wei Jinbao, Shi Jian, Zhu Lijun, Liu Zhongqiu, Wang Yuan, Gao Song, Hu Ming
a Department of Pharmacy , Institute of Wudang Herbal Medicine Research, Taihe Hospital, Hubei University of Medicine , Shiyan , Hubei , China.
b Hubei Provincial Technology and Research Center for Comprehensive Development of Medicinal Herbs, Hubei University of Medicine , Shiyan , Hubei , China.
Drug Metab Rev. 2017 May;49(2):105-138. doi: 10.1080/03602532.2017.1293682. Epub 2017 May 22.
Glucuronidation is a well-recognized phase II metabolic pathway for a variety of chemicals including drugs and endogenous substances. Although it is usually the secondary metabolic pathway for a compound preceded by phase I hydroxylation, glucuronidation alone could serve as the dominant metabolic pathway for many compounds, including some with high aqueous solubility. Glucuronidation involves the metabolism of parent compound by UDP-glucuronosyltransferases (UGTs) into hydrophilic and negatively charged glucuronides that cannot exit the cell without the aid of efflux transporters. Therefore, elimination of parent compound via glucuronidation in a metabolic active cell is controlled by two driving forces: the formation of glucuronides by UGT enzymes and the (polarized) excretion of these glucuronides by efflux transporters located on the cell surfaces in various drug disposition organs. Contrary to the common assumption that the glucuronides reaching the systemic circulation were destined for urinary excretion, recent evidences suggest that hepatocytes are capable of highly efficient biliary clearance of the gut-generated glucuronides. Furthermore, the biliary- and enteric-eliminated glucuronides participate into recycling schemes involving intestinal microbes, which often prolong their local and systemic exposure, albeit at low systemic concentrations. Taken together, these recent research advances indicate that although UGT determines the rate and extent of glucuronide generation, the efflux and uptake transporters determine the distribution of these glucuronides into blood and then to various organs for elimination. Recycling schemes impact the apparent plasma half-life of parent compounds and their glucuronides that reach intestinal lumen, in addition to prolonging their gut and colon exposure.
葡糖醛酸化是包括药物和内源性物质在内的多种化学物质公认的Ⅱ相代谢途径。尽管它通常是继Ⅰ相羟基化之后化合物的次要代谢途径,但仅葡糖醛酸化就可作为许多化合物(包括一些具有高水溶性的化合物)的主要代谢途径。葡糖醛酸化涉及母体化合物通过尿苷二磷酸葡糖醛酸基转移酶(UGTs)代谢为亲水性且带负电荷的葡糖醛酸苷,若无外排转运蛋白的协助,这些葡糖醛酸苷无法离开细胞。因此,在代谢活跃细胞中通过葡糖醛酸化消除母体化合物受两种驱动力控制:UGT酶形成葡糖醛酸苷以及位于各种药物处置器官细胞表面的外排转运蛋白对这些葡糖醛酸苷的(极化)排泄。与通常认为到达体循环的葡糖醛酸苷会经尿液排泄的假设相反,最近的证据表明肝细胞能够高效地经胆汁清除肠道产生的葡糖醛酸苷。此外,经胆汁和肠道消除的葡糖醛酸苷参与涉及肠道微生物的循环方案,这通常会延长它们在局部和全身的暴露时间,尽管全身浓度较低。综上所述,这些最新研究进展表明,尽管UGT决定葡糖醛酸苷生成的速率和程度,但外排和摄取转运蛋白决定这些葡糖醛酸苷在血液中的分布,进而决定其在各个器官中的消除。循环方案不仅会延长母体化合物及其葡糖醛酸苷在肠道和结肠的暴露时间,还会影响到达肠腔的母体化合物及其葡糖醛酸苷的表观血浆半衰期。